| 摘要 |
The invention relates to the use of at least on inhibitor selected from the group consisting of raf-, protein kinase C (PKC)-, MEK1/2-, or ERK1/2-inhibitors, for the manufacturing of a medicament to be administrated from 1 up to 12 hours after initiation of an ischemic disease. |
